Hélène M Faessel (Hélène Faessel)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Topics

Candida Albicans

Top Venues

British journal of clinical pharmacology

Takeda Pharmaceutical Company

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Takeda Pharmaceutical Company Jun 11 2012

United States

Sr Director :: Quantitative Clinical Pharmacology

Publications

Shining Wang, Grace Chen, Emilio Merlo Pich, John Affinito, Michael Cwik, Hélène M Faessel
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers. British journal of clinical pharmacology 88 (6) (2022)
Shining Wang, Grace Chen, Emilio Merlo Pich, John Affinito, Michael Cwik, Hélène M Faessel
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects. British journal of clinical pharmacology 87 (11) (2021)
Hélène M Faessel, John Nemunaitis, Todd M Bauer, A Craig Lockhart, Douglas V Faller, Farhad Sedarati, Xiaofei Zhou, Karthik Venkatakrishnan, R Donald Harvey
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. British journal of clinical pharmacology 85 (7) (2019)
Hélène M Faessel, Diane R Mould, Xiaofei Zhou, Douglas V Faller, Farhad Sedarati, Karthik Venkatakrishnan
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. British journal of clinical pharmacology 85 (11) (2019)